Angel Delgado Garrastegui, MD
Nephrology · Toa Baja, PRNPI 1245644061
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.2% of the total across 67 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AstraZeneca at 24.6% of the total.
Across 67 payments — averaging $42.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$705
- Bayer$231
- Mallinckrodt Hospital Products Inc.$187
- Calliditas Therapeutics US Inc.$185
- Nxstage Medical, Inc.$162
- Akcea Therapeutics, Inc.$158
- plus $1K from 16 others
What the payments were for
- Food & beverage$2,66993%
- Education$1967%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 17 | $705 |
| Bayer | 6 | $231 |
| Mallinckrodt Hospital Products Inc. | 4 | $187 |
| Calliditas Therapeutics US Inc. | 2 | $185 |
| Nxstage Medical, Inc. | 1 | $162 |
| Akcea Therapeutics, Inc. | 1 | $158 |
| GSK | 2 | $157 |
| Lilly USA, LLC | 3 | $147 |
| Vifor Pharma, Inc. | 6 | $136 |
| Insmed, Inc. | 1 | $124 |
| Otsuka America Pharmaceutical, Inc. | 3 | $102 |
| AbbVie | 1 | $99 |
| Apellis Pharmaceuticals, Inc. | 1 | $86 |
| Bard Peripheral Vascular, Inc. | 1 | $82 |
| Amgen(2 entities) | 5 | $77 |
| Fresenius USA Marketing, Inc. | 4 | $67 |
| Daiichi Sankyo Inc. | 3 | $67 |
| ANI Pharmaceuticals, Inc. | 2 | $34 |
| Johnson & Johnson | 1 | $20 |
| Genentech USA, Inc. | 1 | $15 |
| Akebia Therapeutics Inc | 1 | $14 |
| Travere Therapeutics, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$357
- LIBERTY SELECT CYCLER$162
- NXSTAGE SYSTEM ONE$162
- TEGSEDI$158
- TARPEYO$125
- BENLYSTA$112
How this compares
$2,865 in reported general payments places this provider in the 65th percentile of 161 nephrology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 70 | $170,895 |
| FarxigaDapagliflozin Propanediol | 90 | $53,781 |
| Lanthanum Carbonate | 54 | $36,516 |
| Sevelamer Carbonate | 156 | $19,966 |
| LokelmaSodium Zirconium Cyclosilicate | 37 | $19,460 |
| Calcium Acetate | 246 | $18,292 |
| TradjentaLinagliptin | 15 | $11,037 |
| JardianceEmpagliflozin | 14 | $10,918 |
| KerendiaFinerenone | 15 | $9,956 |
| ProsolParenteral Amino Acid 20% No.1 | 30 | $5,509 |
| EliquisApixaban | 12 | $4,790 |
| LantusInsulin Glargine,hum.Rec.Anlog | 45 | $3,606 |
| HumalogInsulin Lispro | 24 | $2,112 |
| Nifedipine ErNifedipine | 74 | $1,764 |
| SynthroidLevothyroxine Sodium | 21 | $1,488 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $67 | $170,89570 claims |
| AstraZenecaFarxiga, Lokelma | $705 | $73,241127 claims |
| BayerKerendia | $231 | $9,95615 claims |
| Lilly USA, LLCHumalog | $147 | $2,11224 claims |
| AbbVieSynthroid | $99 | $1,48821 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $34 | $27414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 161 nephrology providers in Puerto Rico.
Other nephrology in Toa Baja
- Eddie Rodriguez CastroToa Baja$591K
- Ricardo Alicea-GuevaraToa Baja$10K
- Agustin Velazquez PerezToa Baja$5K
- Michelle Cofan HernandezToa Baja$5K
- Luis Diaz CruzToa Baja$3K
- William Hurtado-SantiagoMayaguez$191K
- William Vega OcasioCayey$40K
- Felix Perez RamosPonce$27K
- Antonio JimenezGuaynabo$16K
- Cesar Hernandez-ArroyoTrujillo Alto$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.